fashion -WSS

fashion

author：comprehensive 2025-09-29 13:09:56 - browse：72

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： David Sabatini, ex

focus

WSS

World's first CRISPR

Congress must reauthorize a committee to support older Americans

Free medical tuition alone isn't enough to close gaps in primary care

Obesity drug from Roche shows promise in early study

WuXi Biologics beefs up its lobbying operation

Cherokee Nation medical school graduates its first class

entertainment

fashion

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Poor hospice wound care hurts patients and families

Activists slam private health insurers over coverage restrictions

Abbott's new stent may help patients with peripheral artery disease

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

BioMarin wins approval for gene therapy to treat hemophilia A

Weight loss drug costs may need more research, senator suggests

Drug repurposing or repositioning? The language matters

Childhood cancer progress stalls for Black, Hispanic kids: Report

leisure time

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Abbott's new stent may help patients with peripheral artery disease

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Boston hospital trains restaurant workers on naloxone for overdoses

Hospitals look to new technology to keep health care workers safe

focus

Wikipedia

hotspot

hotspot